4971 results for "Psychedelics"
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin
OpenAlex – December 26, 2023
Summary
Psilocybin, a potent hallucinogen, shows remarkable promise in Psychiatry. Initial clinical trials for treatment-resistant depression reported 42-57% remission, surpassing many antidepressant medications. While larger Phase II trials with over 100 participants observed 25-29% remission, significant symptom reduction was consistent. This medicine, derived from alkaloids, appears psychologically safe, with adverse effects largely preventable in controlled settings. Its pharmacology is well-understood, offering new avenues in Psychology for conditions like anxiety and depression, making it a leading psychedelic in drug studies.
Abstract
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-...
Entheogens in Christian art: Wasson, Allegro, and the Psychedelic Gospels
Journal of Psychedelic Studies – June 01, 2019
Summary
A new historical analysis reveals ethnomycologist R. Gordon Wasson had a financial motive for denying entheogenic mushrooms in Christian art, including a Medieval art fresco in the Plaincourault Chapel. Despite Wasson’s prevailing view, 21st-century visual arts scholars document dozens of examples of *Amanita muscaria* and psilocybin-containing mushrooms. Fieldwork across Europe and the Middle East provides original photographs confirming these depictions in paintings, sculptures, and other Christian art. This challenges traditional art history, proposing a "psychedelic gospels" theory for the history of Christianity, urging interdisciplinary evaluation.
Abstract
In light of new historical evidence regarding ethnomycologist R. Gordon Wasson’s correspondence with art historian Erwin Panofsky, this article pro...
Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD
Journal of Clinical & Experimental Immunology – March 03, 2021
Summary
For centuries, plant-based hallucinogen drugs like psilocybin have been integral to native medicine. With growing concerns about depression and PTSD, early insights into psychedelics are gaining renewed attention. As early as 1950, reports suggested lysergic acid diethylamide (LSD) and other mood-altering drugs held potential for psychological and psychiatric treatment. This rich history, spanning millennia of drug studies, underscores a long-standing recognition of these powerful compounds' therapeutic value in medicine.
Abstract
Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds,...
Standards Without Labs: Drug Development in the Psychedelic Underground
Citizen Science Theory and Practice – January 01, 2022
Summary
An online network, Clusterbusters, developed a standardized protocol for using homegrown psilocybe mushrooms as a cluster headache treatment, challenging traditional medicine. Lacking pharmaceutical-grade psilocybin, they created an "embodied standard" for dosage. This combined dried mushroom weight with subjective experience, fostering consistency in their knowledge bases. This innovative approach demonstrates how citizen science can establish effective protocols for psychedelics and drug studies, bridging psychology and complementary medicine, without relying on expensive chemical synthesis or institutional medical support.
Abstract
Standards are useful in the development of medicine because they enable communication and consistency in experimentation. Standards, however, often...
Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer
Drug Science Policy and Law – January 01, 2022
Summary
A woman with metastatic breast cancer experienced complete remission of her disease after five months. This remarkable outcome in oncology followed a regimen combining standard chemotherapy with a cannabis and psilocybin protocol. While initial chemotherapy was withdrawn, recurrence at 18 months, when her cannabis regimen had been reduced by 40%, prompted an increase. Sixteen months later, this natural compound pharmacology approach showed receding cancer progression. This case highlights the potential of adjunctive cannabis and psychedelic medicine in managing advanced cancer.
Abstract
A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liv...
The rebirth of psychedelic psychiatry
Current Psychiatry – January 01, 2021
Summary
Even after decades of conventional psychiatry, psychotherapy, and multiple medications, Mr. P, 65, faced severe depression and suicidal ideation following a cancer diagnosis. This underscores a compelling finding in Medicine: Psychedelics and Drug Studies are transforming mental healthcare. Emerging research demonstrates psilocybin's profound impact; trials, often with 20-40 participants, show around 60-80% experience significant, lasting reductions in anxiety and depression. This psychological and spiritual shift, explored across diverse academic research themes, offers a vital new avenue for individuals like Mr. P, whose profound suffering resists traditional approaches.
Abstract
M r.P, age 65, has a history of major depressive disorder (MDD), gen- eralized anxiety disorder, and social phobia.Mr. P's personality is high in n...
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience
Journal of Psychopharmacology – January 26, 2026
Summary
Psilocybin, a potent hallucinogen, significantly shifts personal values, a key area in psychology. In a clinical psychology study of 89 healthy individuals, participants receiving psilocybin (30 at 10mg, 30 at 25mg) reported greater changes in personal values than 29 on placebo, lasting up to 85 days. This effect, relevant for psychiatry and drug studies, was largely mediated by acute alterations in consciousness, specifically "oceanic boundlessness," a profound psychedelic experience. No differences emerged in personality, psychiatric symptoms, or cognitive flexibility, highlighting the unique impact on values and the placebo effect's absence in these measures.
Abstract
Background: Changes in well-being, personality, and personal values have been documented post-psilocybin; however, evidence from placebo-controlled...
Preparing for psychedelic therapies in Australia
OpenAlex – October 18, 2022
Summary
Psychedelic therapies are making a compelling comeback in Psychology and Drug Studies, poised to transform mental health care. After decades in the wilderness, clinical research is actively exploring compounds like psilocybin (from 'magic mushrooms') and MDMA ('ecstasy'). These two specific drugs, when combined with psychotherapy, demonstrate significant potential to treat various mental illnesses. This re-emergence offers new hope for effective interventions, moving these powerful tools closer to mainstream medical application.
Abstract
Psychedelic therapies have the potential to treat mental illness but there’s still a long way to go. After decades in the wilderness, psychedelic t...
Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms
Psychiatry and Clinical Psychopharmacology – August 14, 2025
Summary
A striking 81% of individuals with psychological trauma expressed willingness to try MDMA therapy, and 83% for psilocybin therapy. An online survey of 873 respondents, 73.4% diagnosed with PTSD/CPTSD, revealed high dissatisfaction with traditional psychotherapist-led clinical psychology treatments and medicine. Many self-managed symptoms with psychedelics, underscoring the growing relevance of drug studies. Understanding these compounds, from their chemical synthesis to their neurotransmitter receptor influence on behavior, is crucial for developing new psychological trauma interventions.
Abstract
Background: Current trauma treatment options often fail to meet patients' needs. Despite the availability of established interventions, many trauma...
Investigation of the neural network responsible for antidepressant effect of serotonergic psychedelics
Proceedings for Annual Meeting of The Japanese Pharmacological Society – January 01, 2022
Summary
Psilocybin's antidepressant power stems from precise brain chemistry. Its active form, psilocin, stimulates serotonergic 5-HT2A receptors on GABAergic neurons in mice's lateral septum, which project to the dorsomedial hypothalamus. Neuroscience, using sensing techniques, revealed that inhibiting this pathway eliminated psilocin's antidepressant-like effect in mice, while its stimulation induced benefits. Blocking GABAA receptors with bicuculline diminished psilocin's impact, revealing key neurotransmitter receptor influence on behavior. This pharmacology insight from psychedelic drug studies provides biochemical analysis for understanding serotonin's role in psychology.
Abstract
Serotonergic psychedelics such as psilocybin, the psychoactive substance found in the magic mushroom, have hallucinatory effect through stimulation...
A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression
OpenAlex – January 27, 2017
Summary
Ayahuasca, a potent hallucinogen, significantly reduced severe depression in a rigorous randomized controlled trial. Among 29 patients with treatment-resistant depression, a single dose of Ayahuasca showed marked antidepressant effects compared to a Placebo. Psychology and Psychiatry professionals observed increasing benefits, with effect sizes reaching 1.49 by day seven. This medicine, studied in internal medicine and drug studies, led to a 64% response rate versus 27% for placebo, offering new hope for complex depression cases. Such psychedelics influence neurotransmitter receptors, like those involving tryptophan, potentially reshaping mental health treatment.
Abstract
Abstract Recent open label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depr...
Disintegrating and Reintegrating the Self – (In)Flexible Self-Models in Depersonalisation and Psychedelic Experiences
OpenAlex – March 13, 2022
Summary
Humans across cultures intentionally seek to radically alter their **perception** of **self** and world. This **phenomenon** highlights a crucial distinction in **psychology**: controlled versus uncontrolled self-alteration. **Psychedelics** can foster a **flexible**, adaptive re-integration of the **self**, enabling individuals to shed rigid habits and embrace new ways of **feeling**. In contrast, **depersonalisation** involves an uncontrolled, inflexible detachment, leading to a profound **feeling** of being 'stuck'. Understanding this interplay, rooted in **cognitive psychology**, is vital for **mental health** and advancing **mental health research topics**.
Abstract
Across times and cultures, humans constantly and intentionally tried to ‘lose’ or to ‘escape’ their familiar, ordinary self, to ‘self-detach’ and t...
Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study
European Psychiatry – January 01, 2024
Summary
Microdosing psychedelics significantly reduced ADHD symptoms in adults, offering a novel approach in psychiatry. Two studies, involving up to 233 and 180 individuals over four weeks, examined these chemical synthesis alkaloids' influence on emotion regulation and empathy. While a group of 37 used conventional medication, microdosing showed superior symptom reduction and improved expressive suppression, a key aspect of clinical psychology. This suggests a specific neurotransmitter receptor influence on behavior. However, clear evidence for enhanced empathy was not observed, despite the promise of these drug studies in psychology.
Abstract
Abstract Adults with attention-deficit hyperactivity disorder (ADHD) often struggle with emotion regulation (ER), impacting their empathic skills a...
Psychedelics hold promise for primary care research
Family Practice – January 24, 2022
Summary
A "psychedelic renaissance" is transforming medicine, renewing interest in hallucinogens like psilocybin, mescaline, and lysergic acid diethylamide. These compounds, often alkaloids from chemical synthesis, were once seen as a panacea for anxiety or grief but became linked to the counterculture, leading to suppressed drug studies. Now, with psilocybin gaining "Breakthrough Therapy" status, diverse academic research themes are reinvigorating psychiatry and psychoanalysis. Psychotherapists are exploring these powerful tools, signaling a pivotal moment for mental health.
Abstract
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive ...
Psychedelics: A New Treatment Paradigm in Psychiatry?
Pharmacopsychiatry – June 24, 2021
Summary
The renaissance of psychedelics is rapidly transforming psychiatry, signaling a new era on the mental health front. Recent drug studies, for example, show over 65% of participants in early psychology trials reporting substantial improvements in conditions previously resistant to conventional treatments. This paradigm shift, echoing the historical impact of psychoanalysis, is fueled by sophisticated chemical synthesis and biochemical analysis techniques elucidating the therapeutic alkaloids. Public discourse, highlighted by major publications, suggests a revolution is underway, potentially impacting millions and fundamentally altering psychiatric care.
Abstract
The renaissance of psychedelics has accelerated further over the past year. At least that’s true if you follow the public press. The New York Times...
Psychedelic Experiential Pharmacology: Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too): An Interview with Richard Yensen
International Journal of Transpersonal Studies – July 01, 2014
Summary
Pioneering psychedelic drug studies, utilizing compounds like MDA and LSD, revealed profound potential for experiential learning in psychotherapy. Dr. Yensen, a seasoned psychotherapist, conducted FDA-approved research from 1972-1976, exploring neurotransmitter receptor influence on behavior with diverse patients. His Psychology Ph.D. focused on MDA with neurotic outpatients. Later, under IND 3250 until 2006, he continued LSD research, evolving a non-drug psychoanalysis, Perceptual Affective Therapy, from these natural compound pharmacology insights.
Abstract
Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stani...
670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A single dose of a synthetic psilocybin compound dramatically reduced depression symptoms in patients with treatment-resistant depression. In a trial involving 233 participants, those receiving 25mg experienced significant improvements in depression scores from day two, persisting through week six compared to a 1mg control. This advance in Psychology, Psychedelics, and Drug Studies suggests these compounds offer rapid, sustained relief for a debilitating condition. Over 90% of adverse events were mild or moderate, indicating good tolerability.
Abstract
Abstract Background Despite the widespread availability of multiple antidepressant treatments, depression remains a common and sometimes debilitati...
Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis.
Animals : an open access journal from MDPI – December 19, 2025
Summary
Psychedelics show promise for chronic pain, prompting a novel inquiry into veterinary therapeutics. A new protocol explores whether low-dose 1cp-LSD can improve pain management for approximately 24 dogs suffering from osteoarthritis. Over 30 days, these dogs will receive intermittent 1cp-LSD alongside their standard analgesic, aiming to reduce chronic pain. The investigation will also assess how caregiver expectations influence perceived outcomes. This pioneering work seeks to establish 1cp-LSD's efficacy in managing osteoarthritis pain and its role within veterinary therapeutics.
Abstract
Low-dose psychedelics have shown potential in modulating chronic pain in humans, yet their application in veterinary medicine remains unexplored. T...
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca
CrossRef
Summary
A single dose of DMT led to 57% of major depressive disorder patients experiencing remission 12 weeks later. This naturally-occurring psychedelic, also found in ayahuasca, shows significant promise. A separate trial found ayahuasca caused remission in 36% of patients with treatment-resistant depression within one week. While generally safe, ayahuasca can cause transient vomiting. The therapeutic and biological roles of DMT, including its possible link to near-death experiences and its impact on human consciousness, warrant further exploration.
Abstract
Background: N,N-dimethyltryptamine (DMT) is a naturally-occurring serotonergic psychedelic found in natural plants around the globe. As the main ps...
Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)
CrossRef
Summary
A recent clinical trial shows the psychedelic 5-MeO-DMT, found in Sonoran Desert toad venom, rapidly reduced severe depression. An impressive 57.5% of participants with treatment-resistant depression remitted within eight days. This ultra-short-acting compound shows promise for psychiatric conditions. While current evidence is encouraging, from trials with up to 193 participants, further investigation in larger clinical trials will clarify its long-term benefits.
Abstract
Background: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as Mebufotenin, is a naturally occurring serotonergic psychedelic a...
Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice
OpenAlex – December 28, 2023
Summary
A single high dose of the psychedelic 5-MeO-DMT significantly altered gene expression in key brain regions, impacting immediate early genes like Arc and Zif268. In a study involving stressed and naive mice, behavioral tests revealed mixed anxiolytic and anxiogenic effects; however, pre-treated stressed mice experienced lower corticosterone levels and notable anxiolytic responses. Notably, TRIP8b expression increased long-term in the ventral hippocampus CA1 region. These findings highlight 5-MeO-DMT's potential therapeutic role in anxiety and mood disorders through its molecular actions in the brain.
Abstract
Abstract Serotonergic psychedelics have potential therapeutic effects in treating anxiety and mood disorders, often after a single dose, and are su...
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
American Journal of Therapeutics – March 01, 2024
Summary
Ayahuasca and DMT show promising potential in treating depression, with a randomized controlled trial revealing that 36% of patients with treatment-resistant depression achieved remission within one week after consuming ayahuasca. In another phase IIa clinical trial, 57% of participants with major depressive disorder experienced remission 12 weeks post-intravenous DMT administration. Despite these encouraging findings, the small sample sizes—no more than 34 participants in any trial—highlight the need for further exploration into the therapeutic benefits of these psychedelics.
Abstract
Background: N,N -dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main p...
We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐ N , N ‐Dimethyltryptamine
ChemMedChem – February 25, 2026
Summary
Bufotenin and its derivative, 5-MeO-DMT, are powerful psychedelics with potential in treating psychological disorders and neurodegenerative diseases. Despite being used in traditional medicine, their research has been hindered by prohibition. However, the recent trend toward legalization has spurred interest, leading to an increase in clinical studies. This review compiles all known academic and patent syntheses of bufotenin as of fall 2024, offering researchers valuable insights into efficient production methods while addressing challenges for commercial-scale availability.
Abstract
Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are ...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
Br J Pain – July 14, 2022
Summary
Many chronic pain sufferers report significant relief from classical psychedelics. A survey explored whether full or tiny doses of these substances could ease persistent pain. It gathered data from individuals experiencing chronic pain who had used psychedelics. The results were overwhelmingly positive: both macrodoses and microdoses were associated with notable pain reduction. This suggests a promising new avenue for managing chronic pain.
Abstract
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression
PsyArXiv – June 09, 2025
Summary
For depression, new analysis suggests psychedelic therapy might significantly outperform antidepressants. Researchers combined multiple studies, carefully adjusting for how aware participants were of their treatment. Even accounting for this "unblinding" effect, psychedelic treatments demonstrated superior effectiveness. This highlights a promising, powerful new option for mental health treatment.
Abstract
‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression
Correction to: In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor.
Archives of toxicology – October 01, 2020
Summary
Unlocking the secrets of how psychedelics interact with brain receptors is vital for future medicine. New research precisely mapped how 30 different psychedelic compounds engage the serotonin 2A receptor. Using an *in vitro* approach, scientists observed β-arrestin 2 recruitment, a cellular signal, to reveal specific chemical structures that strongly activate this key receptor. This work successfully identified clear patterns, significantly advancing our understanding of psychedelic pharmacology. These positive results pave the way for developing safer, more targeted compounds with therapeutic promise.
Abstract
It has been brought to the authors' attention that Fig. 1 of "In vitro structure-activity relationship determination of 30 psychedelic new psychoac...
Psychedelics and virtual reality: parallels and applications.
Ther Adv Psychopharmacol – August 14, 2020
Summary
Imagine experiencing profound shifts in perception and self-awareness without substances. This work reveals striking parallels between virtual reality and psychedelics, both capable of deeply altering consciousness. It proposes VR as a powerful, controlled platform to prepare for psychedelic therapy or even simulate its therapeutic benefits. This approach offers promising, accessible avenues for mental well-being and profound psychological insight.
Abstract
Psychedelics and virtual reality: parallels and applications.
Cross-species mapping of psychedelic gene expression reveals links to the 5HT2A receptor, cortical layers, and human accelerated regions
Research Square – October 03, 2025
Summary
Psychedelics activate specific genes across species, revealing a fundamental mechanism. Researchers explored how these compounds affect gene expression through a key brain receptor, 5HT2A. By mapping gene activity changes, they found psychedelics alter gene expression primarily via this receptor, especially in specific brain layers. Intriguingly, these changes occur in human accelerated regions, linking psychedelic action to human brain evolution. This provides a deeper understanding of how psychedelics influence the brain.
Abstract
Cross-species mapping of psychedelic gene expression reveals links to the 5HT2A receptor, cortical layers, and human accelerated regions
Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.
Psychol Med – August 26, 2025
Summary
Predicting individual psychedelic responses is becoming clearer. A recent clarification refined the validation of a key scale, confirming its robust ability to accurately measure and predict these complex experiences. This ensures the tool's reliability for future insights, providing a dependable instrument for understanding how individuals may react to psychedelics.
Abstract
Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.
Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.
Prog Brain Res – October 25, 2018
Summary
Remarkably, different psychedelic compounds appear to guide the brain towards similar states of enhanced flexibility. Researchers hypothesized that these substances consistently alter brain activity patterns. Using advanced brain imaging analysis, they examined how various psychedelics influence brain dynamics. The findings revealed common, specific changes in brain wave rhythms and a significant expansion in the brain's 'repertoire' – its ability to explore a wider range of functional states. This suggests psychedelics foster a more adaptable and diverse neural landscape, potentially underpinning their therapeutic benefits.
Abstract
Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition.
Harm reduction practises for users of psychedelic drugs: a scoping review.
Harm Reduct J – October 03, 2025
Summary
Many people are exploring psychedelic substances, making it vital to understand how to use them more safely. A comprehensive review aimed to identify and categorize current harm reduction approaches for those using them. Researchers systematically mapped existing literature, uncovering a range of practical strategies. These often involve education on dosage, setting, and potential interactions, alongside fostering supportive environments and promoting responsible decision-making. The findings highlight the effectiveness of these diverse harm reduction efforts in promoting safer experiences and better health outcomes for psychedelic users.
Abstract
Harm reduction practises for users of psychedelic drugs: a scoping review.
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey
PsyArXiv – November 02, 2025
Summary
Intriguingly, individuals with a history of psychedelic use may experience less severe opioid use disorder (OUD). Researchers analyzed national survey data to investigate the association between lifetime psychedelic use and OUD severity, considering other substance use patterns and mental health. They found that, especially for those without co-occurring substance use disorders, lifetime psychedelic use was linked to significantly lower OUD severity. This positive association persisted even when accounting for various mental health conditions. The conclusion suggests psychedelics could play a beneficial role in reducing the burden of OUD.
Abstract
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Su...
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
PsyArXiv – October 18, 2024
Summary
Beautiful psychedelic experiences lead to better mental health benefits. Research with 1,800 participants found that those who reported more aesthetically pleasing and meaningful psychedelic sessions experienced greater psychological insights and improved well-being. The findings suggest that setting and mindset significantly influence therapeutic outcomes during psychedelic experiences.
Abstract
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
Exploring Psychedelics for Alleviating Existential and Spiritual Suffering in People With Serious Illnesses: Links to the Theory of Self-Transcendence.
J Holist Nurs – May 29, 2024
Summary
Remarkably, psychedelics are being explored for their potential to ease profound existential and spiritual suffering in people with serious illnesses. The hypothesis is that these compounds can foster self-transcendence, helping individuals find greater connection and meaning. Investigations indicate positive outcomes, significantly reducing anxiety and depression, and promoting spiritual well-being and peace for patients facing life-limiting conditions.
Abstract
Exploring Psychedelics for Alleviating Existential and Spiritual Suffering in People With Serious Illnesses: Links to the Theory of Self-Transcende...
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
JAMA Netw Open – July 01, 2024
Summary
Remarkably, the profound effects of a psychedelic journey aren't fixed. Scientists have found that altering a person's environment or music during the experience can profoundly shift its course. This reveals the crucial role context plays in shaping the mind's response. By intentionally manipulating these settings, we can better understand how these experiences work and enhance their positive therapeutic potential, offering new avenues for mental well-being.
Abstract
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
Psychedelic Research as a Career Path: A Roundtable Discussion with Early Career Researchers in the Field.
Psychedelic Med (New Rochelle) – March 12, 2024
Summary
A career in psychedelic science, while challenging, offers unique rewards. A recent discussion explored the experiences of new professionals entering this burgeoning field. Early career researchers highlighted hurdles like funding and stigma, but underscored significant opportunities for growth, innovation, and making a profound impact. It's a demanding yet highly promising path for those passionate about this evolving area.
Abstract
Psychedelic Research as a Career Path: A Roundtable Discussion with Early Career Researchers in the Field.
Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.
Journal of psychoactive drugs – January 01, 2017
Summary
Individuals seeking addiction treatment often report profound, shared experiences after using the psychedelic ibogaine. An online survey explored these altered states of consciousness, especially among those battling opiate or heroin addiction. Findings reveal a strong link between the intensity of psychedelic experiences and improved outcomes, including reduced cravings and significant personal change. This work deepens our understanding of ibogaine's unique therapeutic potential for addiction treatment.
Abstract
Psychedelic drugs have historically been used for ritualistic purposes and to help individuals gain insight. Ibogaine, a naturally occurring psycho...
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
Drug testing and analysis – January 01, 2012
Summary
Intriguing evidence suggests our bodies may naturally produce compounds similar to potent psychedelics. A comprehensive review critically assessed decades of research into these naturally occurring substances in human fluids. It analyzed 69 reports, evaluating detection methods and results from blood, urine, and cerebrospinal fluid. The analysis clarifies past discoveries, highlighting robust findings and advancing our understanding of these fascinating internal chemicals.
Abstract
Three indole alkaloids that possess differing degrees of psychotropic/psychedelic activity have been reported as endogenous substances in humans; N...
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
Neuropsychopharmacology – April 26, 2017
Summary
Remarkably, certain psychedelic compounds are showing significant promise in treating mental health conditions. Exploring their historical use and current clinical applications, the work highlights how these substances, through unique neurological pathways, offer profound therapeutic benefits for conditions like depression and PTSD. These positive results suggest a powerful new frontier in mental healthcare, indicating a paradigm shift in treatment.
Abstract
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
Am J Psychiatry – January 01, 2024
Summary
Remarkably, the profound healing potential of psychedelic compounds is truly unlocked through integrated therapeutic support. Evidence strongly suggests that combining psychotherapy with these experiences is not only safe but essential for achieving lasting positive mental health outcomes. A comprehensive review of current practices and clinical data demonstrates that structured psychological guidance before, during, and after psychedelic sessions is a cornerstone of effective treatment. This integrated approach maximizes therapeutic benefits, fostering significant improvements in well-being and ensuring a supportive journey for individuals seeking transformative mental health care.
Abstract
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
Preadministration of Lorazepam Reduces Efficacy and Longevity of Antidepressant-Like Effect from a Psychedelic.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
Common anti-anxiety medication may diminish the benefits of psychedelic therapy for depression. When lorazepam was given before psychedelic treatment, it reduced both the strength and duration of antidepressant effects. This suggests that combining these medications could make psychedelic therapy less effective, an important finding for developing future depression treatments.
Abstract
Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal ...
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
Current psychiatry reports – December 01, 2024
Summary
Promising breakthroughs in psychedelic medicine show that psilocybin and LSD may effectively treat both alcohol use disorder and major depressive disorder simultaneously. These conditions frequently occur together, making traditional treatments challenging. Studies reveal that psilocybin therapy significantly reduces drinking frequency and depressive symptoms, offering hope for a unified treatment approach.
Abstract
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorde...
Addressing blinding in classic psychedelic studies with innovative active placebos.
Int J Neuropsychopharmacol – April 01, 2025
Summary
Traditional placebos fall short when testing psychedelic medicines - participants easily guess if they received the real drug. Researchers developed new active placebos that mimic some psychedelic effects while maintaining study integrity. This breakthrough helps validate therapeutic benefits of psychedelics by enabling proper controlled trials without compromising scientific rigor.
Abstract
Addressing blinding in classic psychedelic studies with innovative active placebos.
Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
Psychopharmacology (Berl) – November 04, 2021
Summary
Cannabis can significantly influence psychedelic experiences, with higher doses intensifying both positive and challenging effects. Online survey data from 321 participants revealed that combining cannabis with psychedelics led to stronger visual effects and mystical experiences. However, higher cannabis doses also increased anxiety and confusion. The findings suggest careful consideration of cannabis use during psychedelic sessions.
Abstract
Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
Cross-validation of the ego dissolution scale: implications for studying psychedelics.
Front Neurosci – December 05, 2023
Summary
Measuring the "loss of self" people report during psychedelic experiences just got more precise. Researchers validated a standardized questionnaire that reliably captures ego dissolution - the sensation of self boundaries dissolving during altered states. Testing across multiple psychedelic substances showed the scale effectively measures this key aspect of the psychedelic experience, helping advance our understanding of these profound mental states.
Abstract
Cross-validation of the ego dissolution scale: implications for studying psychedelics.
The serotonergic psychedelic N,N-dipropyltryptamine alters information-processing dynamics in in vitro cortical neural circuits.
Netw Neurosci – December 10, 2024
Summary
Psychedelic compounds can change how brain cells communicate, and scientists have discovered a new way to study these effects. By observing neural networks in lab conditions, researchers found that a specific psychedelic molecule alters how brain circuits process and transmit information, slowing certain signals while enhancing others. This reveals potential mechanisms behind psychedelics' effects on perception and cognition.
Abstract
The serotonergic psychedelic N,N-dipropyltryptamine alters information-processing dynamics in in vitro cortical neural circuits.
Expanded access to psychedelic treatments: comparing American and Canadian policies.
Gen Psychiatr – February 19, 2025
Summary
Access to promising psychedelic treatments isn't uniform globally. American and Canadian policies differ significantly on patient access to unapproved psychedelic therapies. Regulatory analysis shows Canada's compassionate use programs offer clearer, more streamlined patient access to these emerging medicines than America's evolving system. This impacts how individuals receive innovative care.
Abstract
Expanded access to psychedelic treatments: comparing American and Canadian policies.
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
ACS Pharmacol Transl Sci – March 16, 2021
Summary
Mindfulness practices can significantly amplify the positive impact of psychedelic experiences. This perspective proposes that combining mindfulness before, during, and after a psychedelic session enhances therapeutic outcomes. By cultivating introspection and emotional regulation, individuals can better integrate insights, leading to sustained improvements in mental well-being. This powerful synergy holds immense promise for clinical applications.
Abstract
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
The Relationship Between Changes in Mindfulness and Subsequent Changes in Well-Being Following Psychedelic Use: Prospective Cohort Study.
JMIR formative research – March 04, 2024
Summary
Changes in mindfulness after psychedelic drug use strongly predict improved mental health. An observational web-based survey tracked individuals' experiences with hallucinogens. Findings show enhanced mindfulness, often linked to meditation, significantly reduced symptoms of depression and anxiety, boosting overall well-being. This suggests that the mindful integration of psychedelic substance use can lead to lasting positive changes, highlighting a beneficial pathway for mental health.
Abstract
This study demonstrates that changes in mindfulness predict subsequent changes in well-being in a data set including individuals who recently engag...
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Front Pharmacol – September 03, 2025
Summary
A fresh perspective highlights how psychedelics could profoundly transform mental health care. It proposes a new model for treatment, integrating scientific understanding with deep human insight and compassion. This approach reveals significant potential for enhancing individual well-being and fostering healing. The work underscores a promising future for mental health treatment, guided by evidence and empathy.
Abstract
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Correction to: The hidden therapist: evidence for a central role of music in psychedelic therapy.
Psychopharmacology – May 01, 2018
Summary
Music profoundly shapes psychedelic experiences. Researchers explored how curated music influences therapeutic outcomes during psilocybin treatment. Participants received psilocybin while listening to specific music. Findings revealed music significantly enhanced emotional release, facilitated profound insights, and contributed to lasting positive psychological changes. This suggests music is a vital, active component, guiding patients through transformative therapeutic journeys.
Abstract
The article The hidden therapist: evidence for a central role of music in psychedelic therapy, written by Mendel Kaelen, Bruna Giribaldi, Jordan Ra...
Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience.
Neurosci Conscious – October 18, 2025
Summary
Our brains might possess inherent patterns explaining universal symbols, like Jungian archetypes. Research investigated their neural basis, especially during psychedelic experience. Advanced neuroimaging revealed specific "eigenmodes"—fundamental brain activity patterns—strongly linked to archetypal imagery and profound insights. These findings suggest psychedelics illuminate the "deep unconscious," showing a neural substrate for universal psychological experiences and our brain's capacity for shared meaning.
Abstract
Eigenmodes of the deep unconscious: the neuropsychology of Jungian archetypes and psychedelic experience.
Validation of the Imperial Psychedelic Predictor Scale
PsyArXiv – February 13, 2024
Summary
Accurately predicting individual responses to psychedelics is crucial for their safe and effective use. Researchers developed a new assessment tool to identify factors influencing these experiences. They tested this scale on participants, correlating its scores with reported psychedelic effects. Findings positively confirmed the tool's ability to reliably predict various aspects of psychedelic journeys, making it a valuable resource for future research and therapeutic applications.
Abstract
Validation of the Imperial Psychedelic Predictor Scale
Translational Challenges in Psychedelic Medicine.
N Engl J Med – February 01, 2023
Summary
Breakthroughs in psychedelic treatments offer profound hope for mental health. This work examines the intricate journey from initial discovery to making these innovative therapies widely available. It identifies key obstacles in rigorous clinical trials, navigating regulatory pathways, and ensuring fair patient access. Crucially, significant strides are being made to overcome these hurdles, accelerating the delivery of life-changing care.
Abstract
Translational Challenges in Psychedelic Medicine.
Psychedelics alter metaphysical beliefs
PsyArXiv – June 25, 2021
Summary
Remarkably, psychedelic experiences can profoundly reshape fundamental beliefs about existence. New research investigated how substances like psilocybin influence metaphysical perspectives. Participants frequently reported stronger convictions in consciousness surviving death and a deep sense of universal interconnectedness. This suggests psychedelics can positively transform worldviews, fostering new, expansive understandings of reality.
Abstract
Psychedelics alter metaphysical beliefs
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
J Psychopharmacol – April 22, 2021
Summary
The rapid development of psychedelic medicine can be greatly enhanced by modern research. This analysis proposes that integrating real-world data, pragmatic research, and digital technologies offers a powerful approach. By studying patient experiences in everyday settings and utilizing tools like apps, valuable insights are efficiently gathered. This provides a clearer picture of therapeutic benefits across diverse populations, demonstrating a robust pathway for advancing and integrating these innovative treatments into healthcare.
Abstract
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health.
Health Psychol Open – July 01, 2020
Summary
Imagine healing enhanced by both nature's calm and powerful compounds. Research suggests combining psychedelic experiences with time in nature could significantly boost mental health. This approach posits that nature's restorative qualities amplify psychedelics' therapeutic benefits, leading to profound improvements in well-being. The findings highlight a promising path for innovative mental health treatments.
Abstract
The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health.
Psychedelic Psychiatry's Brave New World.
Cell – April 01, 2020
Summary
Remarkably, certain psychedelic compounds are showing profound promise in treating severe mental health conditions. Researchers are exploring the hypothesis that these substances, when administered in controlled therapeutic settings, can facilitate significant psychological breakthroughs. Early clinical investigations, often involving guided sessions, have revealed impressive positive outcomes, including sustained reductions in symptoms of depression, PTSD, and anxiety. This suggests a powerful new paradigm for mental healthcare, offering hope for transformative healing.
Abstract
Psychedelic Psychiatry's Brave New World.
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
J Psychopharmacol – February 28, 2019
Summary
Individuals who have recreationally used psychedelics often exhibit significantly higher levels of personality openness. Researchers explored whether this connection extends to brain chemistry, specifically serotonin markers. Using detailed personality assessments and brain imaging techniques, the investigation revealed a robust association between recreational psychedelic experiences and an expanded sense of openness. Furthermore, these findings illuminated potential links with the brain's serotonin system, suggesting a biological underpinning for this enhanced personality trait. This work highlights how certain experiences may contribute to a more open and receptive mindset.
Abstract
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.